Insider Trading (Form 4)
NASDAQ
Cormorant Asset Management, LP reported the sale of 109,331 common shares of Bright Minds Biosciences Inc. at a price of $89.50 per share.
NASDAQ
Cormorant Asset Management, LP reports the acquisition of 184,331 common shares of Bright Minds Biosciences Inc. at $21.7 per share, increasing its total indirect holdings to 1,059,331 shares.
NASDAQ
Cormorant Asset Management, LP reports increased ownership in Bright Minds Biosciences Inc. through a series of open market purchases.
Schedule 13D - Activist Investments
NASDAQ
Ian McDonald reports a reduction in his beneficial ownership of Bright Minds Biosciences Inc. common stock to 13.6% as of July 2, 2026.
Schedule 13G - Passive Investments
See all →NASDAQ
Cormorant Asset Management, LP and Bihua Chen have reported an increase in their beneficial ownership of Bright Minds Biosciences Inc. common shares to 9.17%.
NASDAQ
Adage Capital Management, L.P. and its principals have filed a Schedule 13G, reporting beneficial ownership of 3.41% of Bright Minds Biosciences Inc. common shares.
NASDAQ
Vestal Point Capital, LP and Ryan Wilder have filed a Schedule 13G reporting a 5% beneficial ownership stake in Bright Minds Biosciences Inc.
NASDAQ
Janus Henderson Group plc has filed a Schedule 13G, reporting beneficial ownership of 13.1% of Bright Minds Biosciences Inc. common stock as of March 31, 2026.
NASDAQ
Janus Henderson Group plc has filed a Schedule 13G, reporting beneficial ownership of 13.1% of Bright Minds Biosciences Inc. common stock as of March 31, 2026.
NASDAQ
Vivo Opportunity Fund Holdings, L.P. has filed a Schedule 13G reporting a 5.2% beneficial ownership stake in Bright Minds Biosciences Inc.